Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine

Turcan, Sevin, Fabius, Armida W. M., Borodovsky, Alexandra, Pedraza, Alicia, Brennan, Cameron, Huse, Jason, Viale, Agnes, Riggins, Gregory J. +1 more·2013·Oncotarget
DOI 10.18632/oncotarget.1412

Cited by (242)

Items 201–242 of 242

  1. Diagnostic moléculaire des gliomes diffus
    Audrey Rousseau · 2018 · Revue Francophone des Laboratoires
  2. What's New in Grade II and Grade III Gliomas?
    Wolfgang Wick, Julie J. Miller · 2018 · Seminars in Neurology
  3. Molecular predictors for decitabine efficacy in meningiomas – a pilot study
    Dorothee Cäcilia Spille, Christian Thomas, Andrea Wagner, Oliver Martin Grauer, Julian Canisius, Eva Christine Bunk, Walter Stummer, Hans Theodor Eich, Werner Paulus, Volker Senner et al. · 2023 · Journal of Neuro-Oncology
  4. Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles
    Kenji Fujimoto, Mai Honda‐Kitahara, Naoko Hattori, Yuko Matsushita, Yuko Hibiya, Kaishi Satomi, Hironori Matsunaga, Shinji Tsutsumi, Atsushi Okamoto, Tatsuya Inoue et al. · 2026 · Acta Neuropathologica
  5. Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia
    Lan Ma, Kun Zhang, Yubo Wang, Nan Zheng, Xiaoting Gu, Chao Li, Weiya Li, Ning Li, Yulin Liu, Zhongao Lu et al. · 2026 · Journal of Medicinal Chemistry
  6. Metabolic Enzymes: The Novel Targets for Cancer Stem Cells
    Jianyong Li Peng Li · 2014 · Journal of Stem Cell Research & Therapy
  7. Isocitrate Dehydrogenase (IDH) Mutation in Gliomas
    Charles Chesnelong · 2015 · Springer eBooks
  8. The Association Between Oxidative Stress, Cellular Differentiation And Galectins In Human Promyelocytic Leukemia Cells (HL-60)
    James R. Vinnai · 2016 · Scholarship@Western (Western University)
  9. The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts
    Alastair Davies, Fraser D. Johnson, Kirsi Ketola, Amina Zoubeidi · 2017 · Molecular and translational medicine
  10. Targeting Mitochondrial Enzymes in Pancreatic Cancer
    Gowru Srivani, Begum Dariya, Afroz Alam, Ganji Purnachandra Nagaraju · 2019 · Springer eBooks
  11. The epigenomic impact of methylation in metabolic dysfunction and cancer
    Cynthia A. Zahnow · 2019 · Elsevier eBooks
  12. Experimental Models of Sinonasal Tumors for Preclinical Testing of Candidate Targeted Therapies
    Helena Codina‐Martínez, Sara Lucila Lorenzo‐Guerra, Virginia N. Cabal, Rocío García‐Marín, Cristina Riobello, Laura Suárez–Fernández, Blanca Vivanco, Verónica Blanco‐Lorenzo, Fernando López, Paula Sánchez‐Fernández et al. · 2023 · Current Otorhinolaryngology Reports
  13. BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
    Pavle Boskovic, Nathalie Wilke, Peter Lichter, Liliana Francois, Bernhard Radlwimmer · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  14. An overview of current and future treatment options for adults anaplastic oligodendroglial tumors
    François Ducray, Caroline Dehais, Jean‐Yves Delattre, POLA Network · 2014 · Expert Opinion on Orphan Drugs
  15. Фармакогенетический и биоинженерный подходы к лечению глиальных опухолей головного мозга
    И. С. Брюховецкий, А. С. Брюховецкий, Ю. С. Хотимченко · 2014 · Genes and Cells
  16. Microenvironmental Control of Metastatic Progression
    Calvin D. Roskelley · 2014 · Cancer metastasis
  17. De las doctrinas de la lotería de Babilonia a la medicina de precisión en los gliomas
    Marcelo Andrés Kauffman · 2016 · Neurología Argentina
  18. Epigenetic dysregulation in brain tumors and neurodevelopment
    Marco M. Hefti, Nadejda M. Tsankova · 2016 · Elsevier eBooks
  19. Cell-based models for studying paediatric high-grade gliomas
    Susanna C. Larsson · 2019 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  20. Molecular Therapy for Oligodendrogliomas
    Julie J. Miller, Patrick Yung Wen · 2019 · Elsevier eBooks
  21. Clinical utility of solid tumor epigenetics
    Engin Demirdizen, Julián Taranda, Şevin Turcan · 2021 · Elsevier eBooks
  22. 7267 函館市西部地区の町並み景観の変貌とその要因に関する研究 : -経年的追跡調査による- 2. 変貌の要因と景観誘導の可能性
    満 森下, 富士夫 足達, 孝博 野口, 圭三 山下 · 1992 · 学術講演梗概集. F, 都市計画, 建築経済・住宅問題, 建築歴史・意匠
  23. WITHDRAWN: DNMT inhibitor (decitabine) attenuates tuberculosis-induced spine injury by modulating the expression of microRNA-155 and matrix metalloproteinase-13 via suppressing the hypermethylation of IDH mutant
    Yi Luo, Wenkun Zhang · 2022 · Biochemical and Biophysical Research Communications · Retracted
  24. Faculty Opinions recommendation of IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
    Keith Adam Choate · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  25. Prognostic value of epigenetic markers for canine mast cell cancer
    Shahzar Syed, Britta J. Knight, Geoffrey A. Wood, Brenda Lynn Coomber · 2023 · PLoS ONE
  26. High-Grade Gliomas in Early Adulthood: A Case-Based Review of Current Molecular Diagnostic Considerations
    Leyla Canbeldek, Heather Marion Ames · 2020 · AJSP Review and Reports
  27. Precision neuro-oncology: reality and perspectives
    Jiří Polívka, RASHMI NEGI, Richard Koleják, Jiří Polívka, Pavel Potužník · 2023 · Neurologie pro praxi
  28. Pharmacogenetic and bioengineering approaches to the treatment of glial tumors of the brain
    Igor Bryukhovetskiy, Andrey S. Bryukhovetskiy, Yu. S. Khotimchenko · 2014 · Genes and Cells
  29. Gliomas Difusos do Adulto: Prevalência da Mutação IDH1 em um Hospital Universitário
    Vitor Bonk Rizzo, Michelle Arrata Ramos, Eduardo Morais de Castro, Pedro Helo dos Santos-Neto, Samya Hamad Mehanna · 2025 · Revista Brasileira de Cancerologia
  30. Epigenome in gliomas: novel targets for therapy
    Astik Manju Ashesh, Mohd Qasid Lari, Yogend Chaurasia, Ajay Kumar, Dileep Kumar · 2025 · Elsevier eBooks
  31. Additional file 2 of Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer
    Louis Y. El Khoury, Fu, Shuang, Ryan A. Hlady, Ryan T. Wagner, Wang, Liguo, Eckel-Passow, Jeanette E., Erik P. Castle, Stanton, Melissa L., Thompson, R. Houston, Parker, Alexander S. et al. · 2021 · Figshare
  32. Metabolic Reprogramming in IDH1/2‑Mutant Gliomas: Redox, Anaplerosis, and Therapeutic Vulnerabilities
    Samin Ghasemi, Mehdi Baloochi · 2025 · The Cancer Review
  33. TUBB2A and TM4SF1 Methylation Define Prognostic Subgroups in Adult-Type Diffuse Glioma
    Tarek Ziad Arabi, Itika Arora, Arshiya Akbar, Naveed Syed Abdul Kareem, Zara Ahmed, Volodymyr Mavrych, Olena Bolgova, Shamsa Hilal Saleh, Firoz Ahmed, Ahmed Abu‐Zaid et al. · 2026 · Cancers
  34. Chemotherapy of low-grade astrocytomas
    Raghuram Reddy, Zhijian Chen, Aiden Kong, Mark Gordon Malkin · 2026 · Elsevier eBooks
  35. Molecular mechanisms of pituitary adenoma tumorigenesis and invasiveness
    Mirella P. Hage · 2018
  36. DNA methylation in glioblastoma: insights from single-cell epigenomics
    Rana Zohreh, Nima Rezaei, Parisa Amirifar · 2026 · Epigenomics
  37. Mapping epigenetic alterations across brain tumor hallmarks
    Celeste Antonacci, Luana Abballe, Angela Di Giannatale, Evelina Miele · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  38. The TET Protein Family in Gliomas: Epigenetic Regulation, Molecular Pathogenesis, and Therapeutic Opportunities
    Angelos Kandilas, Dionisis Leimonis, Ioannis Vasilakis, Elisavet Kosma, Christina Piperi · 2026 · Life
  39. Enzyme−Targeted Therapeutics for Neurological Disorders
    Leonardo Massignan, Kanduru Lokesh, Sara Ziadat, David Uehling, Donald Fredric Weaver, Mark A. Reed · 2026 · Journal of Medicinal Chemistry
  40. BindingDB Entry 50022624: Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma.
    BindingDB · 2025 · UC San Diego
  41. BindingDB Entry 50043932: Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
    BindingDB · 2014 · UC San Diego
  42. BindingDB Entry 50008845: Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
    BindingDB · 2021 · UC San Diego